BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
See today's BioWorld
Home
» AVI's DMD Drug Ups Dystrophin, Outcome Distresses Investors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
AVI's DMD Drug Ups Dystrophin, Outcome Distresses Investors
April 3, 2012
By
Karen Carey
No Comments
AVI BioPharma Inc.'s Duchenne's muscular dystrophy (DMD) candidate eteplirsen hit its primary endpoint of significantly increasing dystrophin in a Phase IIb trial, although shares plummeted on Monday over the lack of clinical outcome improvement.
BioWorld